{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:47:56Z","timestamp":1782485276117,"version":"3.54.5"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00120-026-02839-y","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:49:31Z","timestamp":1779112171000},"page":"710-718","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Das nicht-muskelinvasive Urothelkarzinom der Harnblase: Zeit f\u00fcr eine Deeskalation in der Therapie und der Nachsorge","Non-muscle-invasive urothelial carcinoma of the bladder: time for a\u00a0de-escalation of treatment and aftercare"],"prefix":"10.1007","volume":"65","author":[{"given":"Axel","family":"Heidenreich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"2839_CR1","unstructured":"https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Krebsarten\/Harnblasenkrebs\/harnblasenkrebs_node.html, letzter Aufruf 09.04.2026"},{"key":"2839_CR2","unstructured":"https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/harnblasenkarzinom, letzter Aufruf 09.04.2026"},{"key":"2839_CR3","unstructured":"https:\/\/uroweb.org\/guidelines\/non-muscle-invasive-bladder-cancer, letzter Aufruf 09.04.2026"},{"key":"2839_CR4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.euo.2018.05.006","volume":"1","author":"R Hurle","year":"2018","unstructured":"Hurle\u00a0R, Colombo\u00a0P, Lazzeri\u00a0M et\u00a0al (2018) Pathological outcomes for patients who failed to remain under active surveillance for low-risk non-muscle-invasive bladder cancer: update and results from the Bladder Cancer talian Active Surveillance project. Eur Urol Oncol 1:437\u2013442","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"2839_CR5","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.euo.2021.02.007","volume":"4","author":"SK Bhanvadia","year":"2021","unstructured":"Bhanvadia\u00a0SK, Psutka\u00a0SP, Burg\u00a0ML et\u00a0al (2021) Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to Action. Eur Urol Oncol 4(3):396\u2013404","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"2839_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.3055","volume":"5","author":"GS Cook","year":"2022","unstructured":"Cook\u00a0GS, Howard\u00a0JM (2022) Patterns in the Management of Low-Grade Non-Muscle-Invasive Bladder Cancer-the Human and Economic Costs of Excessive Surveillance. JAMA Netw Open 5(3):e223055","journal-title":"JAMA Netw Open"},{"key":"2839_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcpo.2022.100326","volume":"32","author":"JC Michaeli","year":"2022","unstructured":"Michaeli\u00a0JC, Boch\u00a0T, Albers\u00a0S, Michaeli\u00a0T, Michaeli\u00a0DT (2022) Socio-economic burden of disease: Survivorship costs for bladder cancer. J\u00a0Cancer Policy 32:100326","journal-title":"J Cancer Policy"},{"issue":"6","key":"2839_CR8","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/MOU.0000000000001218","volume":"34","author":"JA Kurnot","year":"2024","unstructured":"Kurnot\u00a0JA, Kaye\u00a0DR (2024) Reducing financial toxicity in bladder cancer care. Curr Opin Urol 34(6):484\u2013488","journal-title":"Curr Opin Urol"},{"issue":"10","key":"2839_CR9","doi-asserted-by":"publisher","first-page":"796.e1","DOI":"10.1016\/j.urolonc.2020.04.026","volume":"38","author":"JT Matulay","year":"2020","unstructured":"Matulay\u00a0JT, Tabayoyong\u00a0W, Duplisea\u00a0JJ, Chang\u00a0C, Daneshmand\u00a0S, Gore\u00a0JL, Holzbeierlein\u00a0JM, Karsh\u00a0LI, Kim\u00a0SP, Konety\u00a0BR, Li\u00a0R, McKiernan\u00a0JM, Messing\u00a0EM, Steinberg\u00a0GD, Williams\u00a0SB, Kamat\u00a0AM (2020) Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members. Urol Oncol 38(10):796.e1\u2013796.e6","journal-title":"Urol Oncol"},{"issue":"1","key":"2839_CR10","doi-asserted-by":"publisher","first-page":"9.e19","DOI":"10.1016\/j.urolonc.2021.05.009","volume":"40","author":"JB Kukreja","year":"2022","unstructured":"Kukreja\u00a0JB, Schroeck\u00a0FR, Lotan\u00a0Y et\u00a0al (2022) Discomfort and relieving factors among patients with bladder cancer undergoing office-based cystoscopy. Urol Oncol 40(1):9.e19\u20139.e27","journal-title":"Urol Oncol"},{"key":"2839_CR11","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/jjco\/hye114","volume":"31","author":"S Ozono","year":"2001","unstructured":"Ozono\u00a0S, Hinotsu\u00a0S, Tabata\u00a0S, Takashima\u00a0K, Fujimoto\u00a0K, Okajima\u00a0E et\u00a0al (2001) Treated natural history of superficial bladder cancer. Jpn J Clin Oncol 31:536\u2013540","journal-title":"Jpn J Clin Oncol"},{"key":"2839_CR12","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/S0022-5347(05)65157-9","volume":"167","author":"MS Soloway","year":"2002","unstructured":"Soloway\u00a0MS, Sofer\u00a0M, Vaidya\u00a0A (2002) Contemporary management of stage T1 transitional cell carcinoma of the bladder. J\u00a0Urol 167:1573\u20131583","journal-title":"J Urol"},{"issue":"3","key":"2839_CR13","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s11255-023-03851-3","volume":"56","author":"M Miyake","year":"2024","unstructured":"Miyake\u00a0M, Nishimura\u00a0N, Nishioka\u00a0Y, Fujii\u00a0T, Oda\u00a0Y, Miyamoto\u00a0T, Tomizawa\u00a0M, Shimizu\u00a0T, Owari\u00a0T, Ohnishi\u00a0K, Hori\u00a0S, Morizawa\u00a0Y, Gotoh\u00a0D, Nakai\u00a0Y, Torimoto\u00a0K, Tanaka\u00a0N, Imamura\u00a0T, Fujimoto\u00a0K (2024) Clinical impact of the intensity of follow-up cystoscopy in patients with high-risk non-muscle-invasive bladder cancer. Int Urol Nephrol 56(3):827\u2013837","journal-title":"Int Urol Nephrol"},{"key":"2839_CR14","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.urology.2008.12.061","volume":"73","author":"V Hernandez","year":"2009","unstructured":"Hernandez\u00a0V, Alvarez\u00a0M, de la Pena\u00a0E (2009) Safety of active surveillance program for recurrent nonmuscle-invasive bladder carcinoma. Urology 73:1306","journal-title":"Urology"},{"key":"2839_CR15","doi-asserted-by":"publisher","first-page":"e223050","DOI":"10.1001\/jamanetworkopen.2022.3050","volume":"5","author":"KK Bree","year":"2022","unstructured":"Bree\u00a0KK et\u00a0al (2022) Management, surveillance patterns, and costs associated with low-grade papillary stage Ta non-muscle-invasive bladder cancer among older adults, 2004\u20132013. JAMA Netw Open 5:e223050\u2013e223050","journal-title":"JAMA Netw Open"},{"issue":"18","key":"2839_CR16","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1002\/cncr.32185","volume":"125","author":"FR Schroeck","year":"2019","unstructured":"Schroeck\u00a0FR, Lynch\u00a0KE, Li\u00a0Z et\u00a0al (2019) The impact of frequent cystoscopy on surgical care and cancer outcomes among patients with low-risk, non\u2013muscle-invasive bladder cancer. Cancer 125(18):3147\u20133154","journal-title":"Cancer"},{"issue":"4","key":"2839_CR17","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.3390\/curroncol31040163","volume":"31","author":"D Parrao","year":"2024","unstructured":"Parrao\u00a0D, Lizana\u00a0N, Saavedra\u00a0C, Larra\u00f1aga\u00a0M, Lindsay\u00a0CB, San Francisco\u00a0IF, Bravo\u00a0JC (2024) Active Surveillance in Non-Muscle Invasive Bladder Cancer, the Potential Role of Biomarkers: A Systematic Review. Curr Oncol 31(4):2201\u20132220","journal-title":"Curr Oncol"},{"issue":"2","key":"2839_CR18","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00345-022-04252-4","volume":"41","author":"MCH Hekman","year":"2023","unstructured":"Hekman\u00a0MCH, Wijn\u00a0SRW, Lotan\u00a0Y, Govers\u00a0TM, Witjes\u00a0JA (2023) Bladder EpiCheck urine test in the follow-up of NMIBC: a cost analysis. World J Urol 41(2):471\u2013476","journal-title":"World J Urol"},{"issue":"7","key":"2839_CR19","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/j.1464-410X.2010.10026.x","volume":"108","author":"AM Kamat","year":"2011","unstructured":"Kamat\u00a0AM, Karam\u00a0JA, Grossman\u00a0HB, Kader\u00a0AK, Munsell\u00a0M, Dinney\u00a0CP (2011) Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int 108(7):1119\u20131123","journal-title":"BJU Int"},{"issue":"2","key":"2839_CR20","first-page":"8198","volume":"23","author":"JR Gregg","year":"2016","unstructured":"Gregg\u00a0JR, McCormick\u00a0B, Wang\u00a0L, Cohen\u00a0P, Sun\u00a0D, Penson\u00a0DF, Smith\u00a0JA, Clark\u00a0PE, Cookson\u00a0MS, Barocas\u00a0DA, Resnick\u00a0MJ, Moses\u00a0KA, Chang\u00a0SS (2016) Short term complications from transurethral resection of bladder tumor. Can J Urol 23(2):8198\u20138203","journal-title":"Can J Urol"},{"issue":"1","key":"2839_CR21","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejso.2013.11.003","volume":"40","author":"C De Nunzio","year":"2014","unstructured":"De Nunzio\u00a0C, Franco\u00a0G, Cindolo\u00a0L, Autorino\u00a0R, Cicione\u00a0A, Perdon\u00e0\u00a0S, Falsaperla\u00a0M, Gacci\u00a0M, Leonardo\u00a0C, Damiano\u00a0R, De Sio\u00a0M, Tubaro\u00a0A (2014) Transuretral resection of the bladder (TURB): analysis of complications using a\u00a0modified Clavien system in an Italian real life cohort. Eur J Surg Oncol 40(1):90\u201395","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"2839_CR22","doi-asserted-by":"publisher","first-page":"338.e1","DOI":"10.1016\/j.urolonc.2018.03.015","volume":"36","author":"EIML Liem","year":"2018","unstructured":"Liem\u00a0EIML, McCormack\u00a0M, Chan\u00a0ESY, Matsui\u00a0Y, Geavlete\u00a0P, Choi\u00a0YD, de Reijke\u00a0TM, Farahat\u00a0Y, Inman\u00a0BA, de la Rosette\u00a0JJMCH, Naito\u00a0S (2018) Monopolar vs. bipolar transurethral resection for non-muscle invasive bladder carcinoma: A post-hoc analysis from a randomized controlled trial. Urol Oncol 36(7):338.e1\u2013338.e11","journal-title":"Urol Oncol"},{"issue":"1","key":"2839_CR23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.euo.2024.08.001","volume":"8","author":"R Contieri","year":"2025","unstructured":"Contieri\u00a0R, Soloway\u00a0MS, Gontero\u00a0P, Herr\u00a0H, Kassouf\u00a0W, Mertens\u00a0LS, Moschini\u00a0M, O\u2019Donnell\u00a0M, Palou\u00a0J, Psutka\u00a0SP, Roupr\u00eat\u00a0M, Teoh\u00a0JYC, Kamat\u00a0AM (2025) Deintensification of Treatment for Low-grade Bladder Tumors: A Collaborative Review by the International Bladder Cancer Group (IBCG). Eur Urol Oncol 8(1):179\u2013189","journal-title":"Eur Urol Oncol"},{"key":"2839_CR24","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1097\/00005392-199909010-00019","volume":"162","author":"S Holmang","year":"1999","unstructured":"Holmang\u00a0S et\u00a0al (1999) Recurrence and progression in low grade papillary urothelial tumors. J\u00a0Urol 162:702\u2013702","journal-title":"J Urol"},{"key":"2839_CR25","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/S0022-5347(05)65168-3","volume":"167","author":"S Holmang","year":"2002","unstructured":"Holmang\u00a0S et\u00a0al (2002) Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. J\u00a0Urol 167:1634","journal-title":"J Urol"},{"key":"2839_CR26","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.juro.2006.10.048","volume":"177","author":"P Mariappan","year":"2007","unstructured":"Mariappan\u00a0P et\u00a0al (2007) Pattern of recurrence changes in noninvasive bladder tumors observed during 2\u00a0decades. J\u00a0Urol 177:867\u2013867","journal-title":"J Urol"},{"key":"2839_CR27","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)66443-9","volume":"165","author":"S Holmang","year":"2001","unstructured":"Holmang\u00a0S et\u00a0al (2001) Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J\u00a0Urol 165:1124","journal-title":"J Urol"},{"key":"2839_CR28","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1097\/01.ju.0000149163.08521.69","volume":"173","author":"P Mariappan","year":"2005","unstructured":"Mariappan\u00a0P et\u00a0al (2005) A surveillance schedule for G1Ta bladder cancer allowing efficient use of check cystoscopy and safe discharge at 5 years based on a 25-year prospective database. J\u00a0Urol 173:1108","journal-title":"J Urol"},{"issue":"3 Pt 1","key":"2839_CR29","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S0022-5347(05)67280-1","volume":"164","author":"F Millan-Rodriguez","year":"2000","unstructured":"Millan-Rodriguez\u00a0F, Millan-Rodriguez\u00a0F et\u00a0al (2000) Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J\u00a0Urol 164(3 Pt 1):680\u2013684","journal-title":"J Urol"},{"key":"2839_CR30","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/01.ju.0000076621.71247.6c","volume":"170","author":"MS Soloway","year":"2003","unstructured":"Soloway\u00a0MS et\u00a0al (2003) Expectant management of small, recurrent, noninvasive papillary bladder tumors. J\u00a0Urol 170:438","journal-title":"J Urol"},{"issue":"10","key":"2839_CR31","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.3390\/cancers17101714","volume":"17","author":"M Campistol","year":"2025","unstructured":"Campistol\u00a0M, Lozano\u00a0F, Carrion\u00a0A, Ravent\u00f3s\u00a0CX, Morote\u00a0J, Trilla\u00a0E (2025) Active Surveillance in Non-Muscle Invasive Bladder Cancer: A Systematic Review. Cancers (Basel) 17(10):1714\u20131714","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2839_CR32","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.euo.2021.05.002","volume":"5","author":"R Contieri","year":"2022","unstructured":"Contieri\u00a0R, Paciotti\u00a0M, Lughezzani\u00a0G, Buffi\u00a0NM, Frego\u00a0N, Diana\u00a0P, Fasulo\u00a0V, Saita\u00a0A, Casale\u00a0P, Lazzeri\u00a0M, Guazzoni\u00a0G, Hurle\u00a0R (2022) Long-term Follow-up and Factors Associated with Active Surveillance Failure for Patients with Non-muscle-invasive Bladder Cancer: The Bladder Cancer Italian Active Surveillance (BIAS) Experience. Eur Urol Oncol 5(2):251\u2013255","journal-title":"Eur Urol Oncol"},{"key":"2839_CR33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.euros.2025.10.017","volume":"82","author":"M Finati","year":"2025","unstructured":"Finati\u00a0M, Schiavone\u00a0N, Barone\u00a0B, Contieri\u00a0R, Fanelli\u00a0A, Cinelli\u00a0F, Ricapito\u00a0A, d\u2019 Altilia\u00a0N, Falagario\u00a0UG, Naspro\u00a0R, Pandolfo\u00a0SD, Crocetto\u00a0F, Imbimbo\u00a0C, Bettocchi\u00a0C, Cormio\u00a0L, Carrieri\u00a0G, Pradere\u00a0B, Busetto\u00a0GM (2025) Refining Active Surveillance Eligibility in Intermediate-risk Non-muscle-invasive Bladder Cancer: The Impact of Time to First Recurrence. Eur Urol Open Sci 82:155\u2013159","journal-title":"Eur Urol Open Sci"},{"key":"2839_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2015.11.005","volume":"34","author":"V Hernandez","year":"2016","unstructured":"Hernandez\u00a0V, Llorente\u00a0C, de la Pena\u00a0E et\u00a0al (2016) Long-term oncological outcomes of an active surveillance program in recurrent low grade Ta bladder cancer. Urol Oncol 34:165.e19","journal-title":"Urol Oncol"},{"key":"2839_CR35","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S0022-5347(05)64555-7","volume":"168","author":"H Herr","year":"2002","unstructured":"Herr\u00a0H, Donat\u00a0SM, Dalbagni\u00a0G (2002) Correlation of cystoscopy with histology of recurrent papillary tumors oft he bladder. J\u00a0Urol 168:978\u2013980","journal-title":"J Urol"},{"issue":"Suppl 1","key":"2839_CR36","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.4111\/icu.2016.57.S1.S4","volume":"57","author":"M Miyake","year":"2016","unstructured":"Miyake\u00a0M, Fujimoto\u00a0K, Hirao\u00a0Y (2016) Active surveillance for nonmuscle invasive bladder cancer. Investig Clin Urol 57(Suppl 1):S4\u2013S13","journal-title":"Investig Clin Urol"},{"key":"2839_CR37","volume":"27","author":"F Petrelli","year":"2021","unstructured":"Petrelli\u00a0F, Giannatempo\u00a0P, Maccagnano\u00a0C, Contieri\u00a0R, Hurle\u00a0R (2021) Active surveillance for non-muscle invasive bladder cancer: A systematic review and pooled-analysis. Cancer Treat Res Commun 27:100369","journal-title":"Cancer Treat Res Commun"},{"key":"2839_CR38","doi-asserted-by":"crossref","unstructured":"Kitamura H, Tsukamoto T, Kakehi Y, Mizusawa J, Shibata T, Sasaki K, Tanikawa T, Hashine K, Fujimoto K, Masumori N, Kobayashi T, Habuchi T, Kimura T, Sugimoto M, Takahashi A, Adachi H, Matsui Y, Hatakeyama S, Ito A, Eto M, Nishiyama H; Urologic Oncology Study Group of the Japan Clinical Oncology Group. Active Surveillance Versus Intravesical Bacillus Calmette-Guerin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase\u00a03 JCOG1019 Trial. Eur Urol. 2026 Jan 21:S0302\u20132838(26)00014\u2011X. https:\/\/doi.org\/10.1016\/j.eururo.2026.01.008. Online ahead of print.","DOI":"10.1016\/j.eururo.2026.01.008"},{"issue":"5","key":"2839_CR39","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/JU.0000000000003639","volume":"210","author":"WS Tan","year":"2023","unstructured":"Tan\u00a0WS, Contieri\u00a0R, Buffi\u00a0NM, Lughezzani\u00a0G, Grajales\u00a0V, Soloway\u00a0M, Casale\u00a0P, Hurle\u00a0R, Kamat\u00a0AM (2023) International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance. J\u00a0Urol 210(5):763\u2013770","journal-title":"J Urol"},{"issue":"1","key":"2839_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-024-05417-z","volume":"43","author":"P Zaurito","year":"2024","unstructured":"Zaurito\u00a0P, Scilipoti\u00a0P, Longoni\u00a0M, de Angelis\u00a0M, Re\u00a0C, Quarta\u00a0L, Tremolada\u00a0G, Burgio\u00a0G, Pellegrino\u00a0F, Rosiello\u00a0G, Necchi\u00a0A, Colombo\u00a0R, Gandaglia\u00a0G, Salonia\u00a0A, Montorsi\u00a0F, Briganti\u00a0A, Moschini\u00a0M (2024) Identifying optimal candidates for active surveillance in low-grade intermediate-risk non-muscle invasive bladder cancer. World J Urol 43(1):52","journal-title":"World J Urol"},{"issue":"3","key":"2839_CR41","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3233\/BLC-201535","volume":"7","author":"RM Reyes","year":"2021","unstructured":"Reyes\u00a0RM, Rios\u00a0E, Barney\u00a0S, Hugen\u00a0CM, Michalek\u00a0JE, Lotan\u00a0Y, Messing\u00a0EM, Svatek\u00a0RS (2021) A Randomized Feasibility Trial Comparing Surveillance Regimens for Patients with Low and Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer. Bladder Cancer 7(3):285\u2013295","journal-title":"Bladder Cancer"},{"issue":"1","key":"2839_CR42","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3233\/BLC-220027","volume":"9","author":"ML Creswell","year":"2023","unstructured":"Creswell\u00a0ML, Sholklapper\u00a0TN, Markel\u00a0MJ, Mason\u00a0JB, Pianka\u00a0MA, Dall\u00a0CP, Ulu\u00a0C, Stamatakis\u00a0L (2023) Economic Outcomes of Hexaminolevulinate Blue-Light Cystoscopy in Non-Muscle Invasive Bladder Cancer: A 5\u2011Year, Medicare-Based Model. Bladder Cancer 9(1):87\u201396","journal-title":"Bladder Cancer"},{"key":"2839_CR43","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1007\/s00464-012-2387-0","volume":"26","author":"A Lapini","year":"2012","unstructured":"Lapini\u00a0A, Minervini\u00a0A, Masala\u00a0A, Schips\u00a0L, Pycha\u00a0A, Cindolo\u00a0L, Giannella\u00a0R, Martini\u00a0T, Vittori\u00a0G, Zani\u00a0D, Bellomo\u00a0F, Cunico\u00a0SC (2012) A comparison of hexaminolevulinate (Hexvix(\u00ae)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study. Surg Endosc 26:3634\u20133641","journal-title":"Surg Endosc"},{"issue":"5","key":"2839_CR44","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.juro.2017.11.096","volume":"199","author":"S Daneshmand","year":"2018","unstructured":"Daneshmand\u00a0S, Patel\u00a0S, Lotan\u00a0Y, Pohar\u00a0K, Trabulsi\u00a0E, Woods\u00a0M, Downs\u00a0T, Huang\u00a0W, Jones\u00a0J, O\u2019Donnell\u00a0M, Bivalacqua\u00a0T, DeCastro\u00a0J, Steinberg\u00a0G, Kamat\u00a0A, Resnick\u00a0M, Konety\u00a0B, Schoenberg\u00a0M, Jones\u00a0JS, Flexible Blue Light Study Group Collaborators (2018) Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. J\u00a0Urol 199(5):1158\u20131165","journal-title":"J Urol"},{"key":"2839_CR45","unstructured":"Fasulo V, Paciotti M, Lazzeri M, Contieri R, Casale P, Saita A, Lughezzani G, Diana P, Frego N, Avolio PP, Colombo P, Elefante GM, Guazzoni G, Buffi NM, Bates M, Hurle R. Xpert Bladder Cancer Monitor May Avoid Cystoscopies in Patients Under \u201cActive Surveillance\u201d for Recurrent Bladder Cancer (BIAS Project): Longitudinal Cohort Study."},{"issue":"4","key":"2839_CR46","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.euo.2018.06.011","volume":"1","author":"JA Witjes","year":"2018","unstructured":"Witjes\u00a0JA, Morote\u00a0J, Cornel\u00a0EB, Gakis\u00a0G, van Valenberg\u00a0FJP, Lozano\u00a0F, Sternberg\u00a0IA, Willemsen\u00a0E, Hegemann\u00a0ML, Paitan\u00a0Y, Leibovitch\u00a0I (2018) Performance of the Bladder EpiCheck Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial. Eur Urol Oncol 1(4):307\u2013313","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"2839_CR47","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/bju.14673","volume":"123","author":"D D\u2019Andrea","year":"2019","unstructured":"D\u2019Andrea\u00a0D, Soria\u00a0F, Zehetmayer\u00a0S, Gust\u00a0KM, Korn\u00a0S, Witjes\u00a0JA, Shariat\u00a0SF (2019) Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer. BJU Int 123(6):959\u2013967","journal-title":"BJU Int"},{"issue":"3","key":"2839_CR48","doi-asserted-by":"publisher","first-page":"105.e11","DOI":"10.1016\/j.urolonc.2021.11.001","volume":"40","author":"G Cochetti","year":"2022","unstructured":"Cochetti\u00a0G, de Rossi Vermandois\u00a0JA, Maul\u00e0\u00a0V, Cari\u00a0L, Cagnani\u00a0R, Suvieri\u00a0C, Balducci\u00a0PM, Paladini\u00a0A, Del Zingaro\u00a0M, Nocentini\u00a0G, Mearini\u00a0E (2022) Diagnostic performance of the Bladder EpiCheck methylation test and photodynamic diagnosis-guided cystoscopy in the surveillance of high-risk non-muscle invasive bladder cancer: A\u00a0single centre, prospective, blinded clinical trial. Urol Oncol 40(3):105.e11\u2013105.e18","journal-title":"Urol Oncol"},{"issue":"3","key":"2839_CR49","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3233\/BLC-211528","volume":"7","author":"Y Lotan","year":"2021","unstructured":"Lotan\u00a0Y, Gakis\u00a0G, Manfredi\u00a0M, Morote\u00a0J, Mostafid\u00a0H, Porpiglia\u00a0F, Poyet\u00a0C, Roupret\u00a0M, Schulman\u00a0C, Shariat\u00a0SF, Witjes\u00a0JA (2021) Alternating Cystoscopy with Bladder EpiCheck( ) in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model. Bladder Cancer 7(3):307\u2013315","journal-title":"Bladder Cancer"},{"issue":"3","key":"2839_CR50","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.euo.2018.04.010","volume":"1","author":"Y Lotan","year":"2018","unstructured":"Lotan\u00a0Y, Black\u00a0PC, Caba\u00a0L, Chang\u00a0SS, Cookson\u00a0MS, Daneshmand\u00a0S, Kamat\u00a0AM, McKiernan\u00a0JM, Pruthi\u00a0RS, Ritch\u00a0CR, Steinberg\u00a0GD, Svatek\u00a0RS, Zwarthoff\u00a0EC (2018) Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review. Eur Urol Oncol 1(3):223\u2013230","journal-title":"Eur Urol Oncol"},{"key":"2839_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-026-01137-8","author":"R Contieri","year":"2026","unstructured":"Contieri\u00a0R, Gontero\u00a0P, Hurle\u00a0R, Afferi\u00a0L, Albisinni\u00a0S, Babjuk\u00a0M, Birtle\u00a0A, Black\u00a0P, Brausi\u00a0M, Bruins\u00a0M, \u010capoun\u00a0O, Carrion\u00a0A, Catto\u00a0J, Choudhury\u00a0A, Cimadamore\u00a0A, Comperat\u00a0E, Daneshmand\u00a0S, D\u2019andrea\u00a0D, Del Giudice\u00a0F, Escrig\u00a0JLD, Hensley\u00a0P, Krajewski\u00a0W, Laukhtina\u00a0E, Li\u00a0R, Liedberg\u00a0F, Lotan\u00a0Y, Marcq\u00a0G, Mariappan\u00a0P, Mari\u00a0A, Martini\u00a0A, Lecomte\u00a0AM, Meijer\u00a0R, Mir\u00a0MC, Mori\u00a0K, Moschini\u00a0M, Mostafid\u00a0H, O\u2019Donnell\u00a0M, Palou\u00a0J, Panebianco\u00a0V, Perdon\u00e0\u00a0S, Porten\u00a0S, Psutka\u00a0S, Rink\u00a0M, Roupret\u00a0M, Seisen\u00a0T, Soloway\u00a0M, Soukup\u00a0V, Steinberg\u00a0G, Stenzl\u00a0A, Teoh\u00a0JY, Tully\u00a0K, van der Heijden\u00a0T, van Rhijn\u00a0BWG, Witjes\u00a0A, Xylinas\u00a0E, Kamat\u00a0AM, Pradere\u00a0B, Mertens\u00a0LS (2026) Active surveillance in low-grade NMIBC - results of an international two-round modified Delphi consensus. Nat Rev Urol. https:\/\/doi.org\/10.1038\/s41585-026-01137-8","journal-title":"Nat Rev Urol"},{"key":"2839_CR52","unstructured":"Racioppi M, Di Gianfrancesco L, Ragonese M, Palermo G, Sacco E, Bassi P. Chemoablation with Intensive Intravesical Mitomycin\u00a0C Treatment: A\u00a0New Approach for Non-muscle-invasive Bladder Cancer."},{"issue":"4","key":"2839_CR53","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/JU.0000000000003645","volume":"210","author":"SM Prasad","year":"2023","unstructured":"Prasad\u00a0SM, Huang\u00a0WC, Shore\u00a0ND, Hu\u00a0B, Bjurlin\u00a0M, Brown\u00a0G, Genov\u00a0P, Shishkov\u00a0D, Khuskivadze\u00a0A, Ganev\u00a0T, Marchev\u00a0D, Orlov\u00a0I, Kopyltsov\u00a0E, Zubarev\u00a0V, Nosov\u00a0A, Komlev\u00a0D, Burger\u00a0B, Raju\u00a0S, Meads\u00a0A, Schoenberg\u00a0M (2023) Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS). J\u00a0Urol 210(4):619\u2013629","journal-title":"J Urol"},{"issue":"2","key":"2839_CR54","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/JU.0000000000004296","volume":"213","author":"SM Prasad","year":"2025","unstructured":"Prasad\u00a0SM, Shishkov\u00a0D, Mihaylov\u00a0NV, Khuskivadze\u00a0A, Genov\u00a0P, Terzi\u00a0V, Kates\u00a0M, Huang\u00a0WC, Louie\u00a0MJ, Raju\u00a0S, Burger\u00a0B, Meads\u00a0A, Schoenberg\u00a0M (2025) Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION). J\u00a0Urol 213(2):205\u2013216","journal-title":"J Urol"},{"key":"2839_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2026.03.008","author":"S Klingenberg","year":"2026","unstructured":"Klingenberg\u00a0S, Lindgren\u00a0MS, Jakobsen\u00a0JK, Jensen\u00a0JB, Kingo\u00a0PS (2026) DaBlaCa-13 Study: Five-year Follow-up from the Randomized Controlled Trial of Chemoresection with Intravesical Mitomycin C in Recurrent Ta Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2026.03.008","journal-title":"Eur Urol Oncol"},{"key":"2839_CR56","doi-asserted-by":"crossref","unstructured":"Pedersen GL, Mogensen K, Rosth\u00f8j S, Erikson MS, Fode M, Hermann GG. In-Office Laser Coagulation of Ta Bladder Tumor Compared with Transurethral Resection of Bladder Tumor: 12\u00a0Months Follow-Up Randomized Clinical Trial J Urol. 2026 Jan 13:101097JU0000000000004918. https:\/\/doi.org\/10.1097\/JU.0000000000004918. Online ahead of print.","DOI":"10.1097\/JU.0000000000004918"},{"issue":"5","key":"2839_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15051939","volume":"15","author":"MT Melgarejo Segura","year":"2026","unstructured":"Melgarejo Segura\u00a0MT, Herraez Marcos\u00a0M, Cano Garcia\u00a0MC, Zambudio Munuera\u00a0A, Rodriguez Parras\u00a0P, Arrabal Polo\u00a0MA (2026) De-Intensification Strategies in Non-Muscle-Invasive Bladder Cancer: Outcomes and Cost Impact of In-Office Bladder Fulguration. J\u00a0Clin Med 15(5):1939","journal-title":"J Clin Med"},{"issue":"5","key":"2839_CR58","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/bju.12216","volume":"112","author":"KA Wong","year":"2013","unstructured":"Wong\u00a0KA, Zisengwe\u00a0G, Athanasiou\u00a0T, O\u2019Brien\u00a0T, Thomas\u00a0K (2013) Outpatient laser ablation of non-muscle-invasive bladder cancer: is it safe, tolerable and cost-effective? BJU Int 112(5):561\u2013567","journal-title":"BJU Int"},{"issue":"3","key":"2839_CR59","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/bju.16269","volume":"133","author":"C Vitug","year":"2024","unstructured":"Vitug\u00a0C, Lajkosz\u00a0K, Chavarriaga\u00a0J, Llano\u00a0A, Din\u00a0S, Villegas\u00a0E, Kuk\u00a0C, Chan\u00a0A, Gao\u00a0B, Hemminki\u00a0O, Kot\u00a0D, Misurka\u00a0J, van der Kwast\u00a0TH, Wallis\u00a0C, Jewett\u00a0MAS, Soloway\u00a0MS, Fleshner\u00a0NE, Kulkarni\u00a0GS, Zlotta\u00a0AR (2024) Long-term outcomes and cost savings of office fulguration of papillary Ta low-grade bladder cancer. BJU Int 133(3):289\u2013296","journal-title":"BJU Int"},{"issue":"2","key":"2839_CR60","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.urology.2014.09.041","volume":"85","author":"B Al Hussein Al Awamlh","year":"2015","unstructured":"Al Hussein Al Awamlh\u00a0B, Lee\u00a0R, Chughtai\u00a0B, Donat\u00a0SM, Sandhu\u00a0JS, Herr\u00a0HW (2015) A cost-effectiveness analysis of management of low-risk non-muscle-invasive bladder cancer using office-based fulguration. Urology 85(2):381\u2013386","journal-title":"Urology"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02839-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-026-02839-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02839-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:04:40Z","timestamp":1782482680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-026-02839-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2839"],"URL":"https:\/\/doi.org\/10.1007\/s00120-026-02839-y","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"9 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Heidenreich gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}